Cargando…
Fluvoxamine for aripiprazole-associated akathisia in patients with schizophrenia: a potential role of sigma-1 receptors
BACKGROUND: Second-generation antipsychotic drugs have been reported to cause fewer incidences of extrapyramidal side effects (EPSs) than typical antipsychotic drugs, but adverse events such as akathisia have been observed even with atypical antipsychotic drugs. Although understanding of the pathoph...
Autores principales: | Furuse, Tsutomu, Hashimoto, Kenji |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2847563/ https://www.ncbi.nlm.nih.gov/pubmed/20205742 http://dx.doi.org/10.1186/1744-859X-9-11 |
Ejemplares similares
-
Fluvoxamine for blonanserin-associated akathisia in patients with schizophrenia: report of five cases
por: Furuse, Tsutomu, et al.
Publicado: (2010) -
Fluvoxamine monotherapy for psychotic depression: the potential role of sigma-1 receptors
por: Furuse, Tsutomu, et al.
Publicado: (2009) -
Sigma-1 receptor agonist fluvoxamine for delirium in patients with Alzheimer's disease
por: Furuse, Tsutomu, et al.
Publicado: (2010) -
Benefical Effects of Sigma-1 Agonist Fluvoxamine for Tardive Dyskinesia and Tardive Akathisia in Patients with Schizophrenia: Report of Three Cases
por: Albayrak, Yakup, et al.
Publicado: (2013) -
Sigma-1 receptor agonist fluvoxamine for delirium in intensive care units: report of five cases
por: Furuse, Tsutomu, et al.
Publicado: (2010)